Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 18, Issue 5, Pages 614-627Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161212799315984
Keywords
Cystic fibrosis; lung disease; therapy
Categories
Ask authors/readers for more resources
Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that lead to abnormalities in transepithelial ion transport in the airways of affected patients. Lung disease is the major contributor to morbidity and mortality in patients with cystic fibrosis but recommended therapeutic interventions so far have focussed on symptom control rather than treatment of the underlying causes of the disease. New therapies that are currently in pre-clinical and clinical testing include CFTR pharmacotherapy, drugs targeting other ion channels, and hydrators of the cystic fibrosis airways. The current status of these and other new developments in the treatment of cystic fibrosis are reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available